^
    Back
    Association details:
    Biomarker:LDHB-L + PD-L1 expression
    Cancer:Melanoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor) +
    Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2020
    Title:

    Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study

    Published date:
    09/14/2020
    Excerpt:
    In pts with LDH ≤ULN at baseline, PFS and DOR benefit with A+V+C were greater for the PD-L1+ subgroup. Conversely, in pts with LDH >ULN, benefit with A+V+C was greater in the PD-L1– subgroup.
    Trial ID:
    IMspire150